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Abstract
Locally advanced squamous cell carcinoma of the head and neck (SCCHN) that is not associated
with human papillomavirus (HPV) has a poor prognosis in contrast to HPV-positive disease. To
better understand the importance of RB1 activity in HPV-negative SCCHN, we investigated the
prognostic value of inhibitory CDK4/6 phosphorylation of RB1 on threonine 356 (T356) in archival
HPV-negative tumor specimens from patients who underwent surgical resection and adjuvant
radiation. We benchmarked pT356RB1 to total RB1, Ki67, pT202/Y204ERK1/2, and TP53, as quantified
by automatic quantitative analysis (AQUA), and correlated protein expression with tumor stage
and grade. High expression of pT356RB1 but not total RB1 predicted reduced overall survival (OS;
P = 0.0295), indicating the potential relevance of post-translational phosphorylation. Paired
analysis of The Cancer Genome Atlas (TCGA) data for regulators of this RB1 phosphorylation
identified  loss  or  truncating  mutation  of  negative  regulator  CDKN2A  (p16)  and  elevated
expression of the CDK4/6 activator CCND1 (cyclin D) as also predicting poor survival. Given that
CDK4/6 inhibitors have been most effective in the context of functional RB1 and low expression
or deletion of p16 in other tumor types, these data suggest such agents may merit evaluation in
HPV-negative SCCHN, specifically in cases associated with high pT356RB1.
Keywords
Biomarkers, CDK4/6, E2F, Head and neck cancer, RB1
